Craig-Hallum initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Approves Amendments at Annual Stockholders Meeting
- Neurogene price target raised to $26 from $22 at BMO Capital
- Neurogene Highlights Gene Therapy Advancements in New Update
- Neurogene Reports Q1 2025 Financial Progress and Updates
- Optimistic Buy Rating for Neurogene Amid Favorable Market and Regulatory Conditions